ファーマコビジランスの世界市場2020-2027:製品ライフサイクル別、サービスプロバイダー別、種類別、治療領域別、プロセスフロー別、最終用途別

◆英語タイトル:Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider, By Type, By Therapeutic Area, By Process Flow, By End-use, And Segment Forecasts, 2020 - 2027
◆商品コード:GV20NV185
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2020年10月20日
◆ページ数:265
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥618,800見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥722,800見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥930,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、ファーマコビジランスの世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場要因・動向・範囲、新型コロナウイルスの影響分析、サービスプロバイダー別(家庭内、契約アウトソーシング)分析、種類別(自発的報告、強化ADRレポート、ターゲット自発的レポート、コホートイベントモニタリング、EHRマイニング)分析、製品ライフサイクル別(前臨床、フェーズI、フェーズII、フェーズIII、フェーズIV)分析、プロセスフロー別(ケースデータ管理、信号検出、リスク管理システム)分析、治療領域別(腫瘍、神経、心臓病、呼吸器系、その他)分析、最終用途別(医薬品、バイオテクノロジー企業、医療機器メーカー、その他)分析、地域別分析、競争分析、企業概要、戦略、スイッチングコスト分析などを整理しました。
・調査手法・範囲
・エグゼクティブサマリー
・市場要因・動向・範囲
・新型コロナウイルスの影響分析
・ファーマコビジランスの世界市場規模:サービスプロバイダー別(家庭内、契約アウトソーシング)
・ファーマコビジランスの世界市場規模:種類別(自発的報告、強化ADRレポート、ターゲット自発的レポート、コホートイベントモニタリング、EHRマイニング)
・ファーマコビジランスの世界市場規模:製品ライフサイクル別(前臨床、フェーズI、フェーズII、フェーズIII、フェーズIV)
・ファーマコビジランスの世界市場規模:プロセスフロー別(ケースデータ管理、信号検出、リスク管理システム)
・ファーマコビジランスの世界市場規模:治療領域別(腫瘍、神経、心臓病、呼吸器系、その他)
・ファーマコビジランスの世界市場規模:最終用途別(医薬品、バイオテクノロジー企業、医療機器メーカー、その他)
・ファーマコビジランスの世界市場規模:地域別
・競争動向
・企業概要
・戦略
・スイッチングコスト分析
【レポートの概要】

Pharmacovigilance Market Growth & Trends

The global pharmacovigilance market size is expected to reach USD 13.11 billion by 2027, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 13.2% during the forecast period. The increasing incidence of Adverse Drug Reactions (ADR) is the key growth driver. ADR imposes a substantial burden on healthcare systems and is one of the prominent causes of morbidity in developed countries. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in Europe each year, are due to ADR. Pharmacovigilance services play an integral role in this clinical trial phase by assisting manufacturers in identifying adverse effects associated with the drug.

According to the World Health Organization’s (WHO) report on pharmaceutical consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in non-hospital setups. Hence, there has been a significant rise in the number of medicines made available to healthcare consumers. Rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.

Moreover, leading pharma companies in developed countries are focusing on outsourcing PV services to reduce cost and to minimize operational expenses. This is anticipated to serve as an opportunity for contact research organizations in developing regions to gain more revenue share. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.

The companies operating in the pharmacovigilance market are undertaking strategic initiatives, such as collaborations with the PV service providers to gain access to medical information and to manage PV workflows. For instance, in September 2019, Accenture collaborated with Bayer to implement the company’s INTIENT Clinical platform to simplify and speed its drug development processes, thereby widening business. The company collaborated with BioCelebrate in 2017 to develop a platform for aggregating and analyzing clinical information for improved drug developing efficiency, thus enhancing its R&D capabilities. Such initiatives help companies maintain their market position.

Pharmacovigilance Market Report Highlights

• Phase IV held a dominant market share at 75.56% in 2019 owing to the extensive post-marketing surveillance of pharmaceuticals and an increasing number of ADR incidences in the market

• In the service provider segment, contract outsourcing held a significant market share of around 57% as of 2019, owing to the shift in focus of pharmaceutical companies to outsourcing services to reduce operational cost

• Based on types, spontaneous reporting held the largest revenue share due to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison

• The biotechnology segment is anticipated to exhibit a lucrative CAGR of 13.9% over the forecast period owing to increasing R&D for the development of novel biologics

• Asia Pacific is anticipated to showcase a lucrative CAGR of 14.9% in the forthcoming years. This is attributing to the availability of low-cost labor and the rising number of outsourcing companies in this region

• Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services. Moreover, companies are adopting strategies including new product launch, collaborations, and mergers & acquisitions to gain a competitive advantage

【レポートの目次】

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Service Provider
1.1.2 Type
1.1.3 Product Life Cycle
1.1.4 Process Flow
1.1.5 Therapeutic area
1.1.6 End-use
1.1.7 Regional Scope
1.1.8 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews in North America
1.3.5.2 Data for Primary Interviews in Europe
1.3.5.3 Data for Primary Interviews in APAC
1.3.5.4 Data for Primary Interviews in Latin America
1.3.5.5 Data for Primary Interviews in MEA
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Market Definitions
1.9.1 Product Life Cycle
1.9.1.1 Preclinical
1.9.1.2 Phase I
1.9.1.3 Phase II
1.9.1.4 Phase III
1.9.1.5 Phase IV
1.9.2 Type of Methods Outlook
1.9.2.1 Spontaneous reporting
1.9.2.2 Intensified ADR Reporting
1.9.2.3 Targeted Spontaneous Reporting
1.9.2.4 Cohort Event Monitoring
1.9.2.5 EHR Mining
1.9.3 Service Providers Outlook
1.9.3.1 In-house
1.9.3.2 Outsourcing
1.9.4 End-use Outlook
1.9.4.1 Pharmaceuticals & Biotechnology Companies
1.9.4.2 Medical Device Manufacturers
1.10 Report Objectives
1.10.1 Objective 1
1.10.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Pharmacovigilance Market Outlook, 2016-2027 (USD Million)
2.3 Segment Outlook
2.4 Competitive Outlook
Chapter 3 Pharmacovigilance Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market analysis
3.1.2 Ancillary market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Pharmacovigilance Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Growing drug consumption and drug development rates
3.3.1.2 Increasing incidence of ADR and drug toxicity
3.3.1.3 Increasing trend of outsourcing pharmacovigilance services
3.3.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
3.3.1.5 Increasing regulatory burden on manufacturers
3.3.1.6 Introduction of technologically advanced software services
3.3.1.7 Constantly rising investment on R&D by healthcare companies
3.3.1.8 Partnerships and collaborations between market players
3.3.2 Market restraint analysis
3.3.2.1 Shortage of skilled labor
3.3.2.2 Expensive technology for small and mid-sized player
3.3.2.3 Lack of recognition
3.3.2.4 Scarcity of integration standards
3.3.3 Industry Challenges
3.4 Pharmacovigilance Market Analysis Tools: Porters
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Value Chain Analysis
3.6.1 Preclinical
3.6.2 Clinical
3.6.3 PMA
3.7 Mapping of Life Cycle Against Service Offering And Their Demand
3.8 Regulatory Framework
3.8.1 List of regulatory bodies by Country
3.9 Pharmacovigilance: Organization Structure Introduction
3.10 Pricing Models
3.10.1 Drug Safety Budget Allocation By Activities
3.10.2 By Development phase
3.10.3 By Therapeutic area
3.10.4 Pricing Level
3.10.4.1 Case processing
3.10.4.2 ADR Reporting
3.10.4.3 Medical writing
3.10.4.4 Drug safety management
3.11 Technology Timeline Overview
3.11.1 Changing Technology & Adoption
3.11.1.1 Social Media
3.11.1.2 Literature screening
3.11.1.3 Automation and AI
3.11.1.4 Big data analytics in PV
Chapter 4 COVID-19 Impact Analysis
4.1 COVID-19 Outbreak
4.1.1 Challenges for safety reporting activities
4.2 Demand Analysis
4.2.1 Product Pipeline Analysis, by Stage for COVID-19
4.3 Recent Developments & Strategic Outcomes
4.3.1 Regulatory requirements/changes due to covid-19
4.3.2 Strategies implemented by companies
4.3.2.1 IQVIA
4.3.2.2 PARAXEL International Corporation
4.3.2.3 Bioclinica
4.3.2.4 Pharmaceutical Product Development (PPD)
4.3.2.5 IBM Corporation
4.3.2.6 ICON, plc
4.3.2.7 PRA Health Sciences
4.3.2.8 Covance Inc
4.3.2.9 ArisGlobal
4.3.2.10 Linical Accelovance
4.3.2.11 Laboratory Corporation of America Holdings
Chapter 5 Pharmacovigilance Market: Service provider Estimates & Trend Analysis
5.1 Service Provider Market Share Analysis, 2019 & 2027
5.2 Service Provider Dashboard
5.2.1 In House
5.2.1.1 In house market estimates and forecasts, 2016 – 2027 (USD Million)
5.2.2 Contract Outsourcing
5.2.2.1 Contract outsourcing market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis
6.1 Type Market Share Analysis, 2019 & 2027
6.2 Type Dashboard
6.2.1 Spontaneous Reporting
6.2.1.1 Spontaneous Reporting market estimates and forecasts, 2016 – 2027 (USD Million)
6.2.2 Intensified ADR Reporting
6.2.2.1 Intensified ADR Reporting market estimates and forecasts, 2016 – 2027 (USD Million)
6.2.3 Targeted Spontaneous Reporting
6.2.3.1 Targeted spontaneous reporting market estimates and forecasts, 2016 – 2027 (USD Million)
6.2.4 Cohort Event Monitoring (CEM)
6.2.4.1 CEM market estimates and forecasts, 2016 – 2027 (USD Million)
6.2.5 EHR Mining
6.2.5.1 EHR Mining market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis
7.1 Product Life Cycle Market Share Analysis, 2019 & 2027
7.2 Product Dashboard
7.2.1 Preclinical
7.2.1.1 Preclinical market estimates and forecasts, 2016 – 2027 (USD Million)
7.2.2 Phase I
7.2.2.1 Phase I market estimates and forecasts, 2016 – 2027 (USD Million)
7.2.3 Phase II
7.2.3.1 Phase II market estimates and forecasts, 2016 – 2027 (USD Million)
7.2.4 Phase III
7.2.4.1 Phase III market estimates and forecasts, 2016 – 2027 (USD Million)
7.2.5 Phase IV
7.2.5.1 Phase IV market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis
8.1 Process Flow Market Share Analysis, 2019 & 2027
8.2 Process Flow Dashboard
8.2.1 Case data management
8.2.1.1 Case data management market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.1.2 Case logging
8.2.1.3 Case logging market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.1.4 Case data analysis
8.2.1.5 Case data analysis market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.1.6 Medical reviewing and reporting
8.2.1.7 Medical reviewing and reporting market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.2 Signal detection
8.2.2.1 Signal detection market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.2.2 Adverse Event Logging
8.2.2.3 Adverse Event Logging market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.2.4 Adverse Event Analysis
8.2.2.5 Adverse Event Analysis market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.2.6 Adverse Event Review & Reporting
8.2.2.7 Adverse Event Review & Reporting market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.3 Risk Management System
8.2.3.1 Risk Management System market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.3.2 Risk Evaluation System
8.2.3.3 Risk Evaluation System market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.3.4 Risk Mitigation System
8.2.3.5 Risk Mitigation System market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis
9.1 Therapeutic Area Market Share Analysis, 2019 & 2027
9.2 Therapeutic Area Dashboard
9.2.1 Oncology
9.2.1.1 Oncology market estimates and forecasts, 2016 – 2027 (USD Million)
9.2.2 Neurology
9.2.2.1 Neurology market estimates and forecasts, 2016 – 2027 (USD Million)
9.2.3 Cardiology
9.2.3.1 Cardiology market estimates and forecasts, 2016 – 2027 (USD Million)
9.2.4 Respiratory systems
9.2.4.1 Respiratory systems market estimates and forecasts, 2016 – 2027 (USD Million)
9.2.5 Others
9.2.5.1 Others market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 10 Pharmacovigilance Market: End-Use Estimates & Trend Analysis
10.1 End-Use Market Share Analysis, 2019 & 2027
10.2 End-Use Dashboard
10.2.1 Pharmaceuticals
10.2.1.1 Pharmaceuticals market estimates and forecasts, 2016 – 2027 (USD Million)
10.2.2 Biotechnology Companies
10.2.2.1 Biotechnology companies market estimates and forecasts, 2016 – 2027 (USD Million)
10.2.3 Medical Device Manufacturers
10.2.3.1 Medical Device Manufacturers market estimates and forecasts, 2016 – 2027 (USD Million)
10.2.4 Others
10.2.4.1 Others market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 11 Pharmacovigilance Market: Regional Estimates & Trend Analysis by Segments
11.1 Regional Market Snapshot
11.2 Market Share Analysis by Country, 2019
11.2.1 North America
11.2.1.1 SWOT Analysis
11.2.2 Europe
11.2.2.1 SWOT Analysis
11.2.3 Asia Pacific
11.2.3.1 SWOT Analysis
11.2.4 Latin America
11.2.4.1 SWOT Analysis
11.2.5 MEA
11.2.5.1 SWOT Analysis
11.3 North America
11.3.1 North America Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.3.2 U.S.
11.3.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2014 – 2026(USD Million)
11.3.3 Canada
11.3.3.1 Canada Pharmacovigilance market estimates and forecasts, 2014 – 2026(USD Million)
11.4 Europe
11.4.1 Europe Pharmacovigilance MARKET estimates and forecasts, 2016 – 2027 (USD Million)
11.4.2 U.K.
11.4.2.1 U.K. Pharmacovigilance market estimates and forecasts, 2014 – 2026(USD Million)
11.4.3 Germany
11.4.3.1 Germany Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.4.4 France
11.4.4.1 France Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.4.5 Italy
11.4.5.1 Italy Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.4.6 Spain
11.4.6.1 Spain pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.4.7 Russia
11.4.7.1 Russia Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.5 Asia Pacific
11.5.1 Asia Pacific Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.5.2 Japan
11.5.2.1 Japan Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.5.3 China
11.5.3.1 China Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.5.4 India
11.5.4.1 India Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.6 Latin America
11.6.1 Latin America Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.6.2 Brazil
11.6.2.1 Brazil Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.6.3 Mexico
11.6.3.1 Mexico Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.7 MEA
11.7.1 MEA Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.7.2 South Africa
11.7.2.1 South Africa Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
11.7.3 Kingdom of Saudi Arabia
11.7.3.1 Kingdom of Saudi Arabia Pharmacovigilance market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 12 Competitive Outlook
12.1 Market Participation Categorization
12.2 Public Companies
12.2.1 Company market position analysis
12.2.2 Company Market Share
12.3 Private Companies
12.3.1 List of key emerging companies
12.4 Consolidation Trends
12.5 Potential Customers
Chapter 13 Company Profiles
13.1 Accenture
13.1.1 Company overview
13.1.2 Service benchmarking
13.1.3 Organization structure & Team Composition
13.1.3.1 Team composition
13.1.4 Financial performance
13.1.5 R&D expenditure
13.1.6 Strategic initiatives
13.1.7 SWOT Analysis
13.2 Clinquest Group B.V. (Linical Americas)
13.2.1 Company overview
13.2.2 Service benchmarking
13.2.3 Organization structure & Team Composition
13.2.3.1 Team composition
13.2.4 Financial performance
13.2.5 Strategic initiatives
13.2.6 SWOT Analysis
13.3 IQVIA
13.3.1 Company overview
13.3.2 Service benchmarking
13.3.3 Organization structure & Team Composition
13.3.3.1 Team composition
13.3.4 Financial performance
13.3.5 Strategic initiatives
13.3.6 SWOT Analysis
13.4 Cognizant
13.4.1 Company overview
13.4.2 Service benchmarking
13.4.3 Organization structure & Team Composition
13.4.3.1 Team composition
13.4.4 Financial performance
13.4.5 Strategic initiatives
13.4.6 SWOT Analysis
13.5 Laboratory Corporation of America Holdings
13.5.1 Company overview
13.5.2 Service benchmarking
13.5.3 Organization structure & Team Composition
13.5.3.1 Team composition
13.5.4 Financial performance
13.5.5 Strategic initiatives
13.5.6 SWOT Analysis
13.6 IBM Corporation
13.6.1 Company overview
13.6.2 Service benchmarking
13.6.3 Organization structure & Team Composition
13.6.3.1 Team composition
13.6.4 Financial performance
13.6.5 R&D expenditure
13.6.6 Strategic initiatives
13.6.7 SWOT Analysis
13.7 ArisGlobal
13.7.1 Company overview
13.7.2 Service benchmarking
13.7.3 Organization structure & Team Composition
13.7.3.1 Team composition
13.7.4 Financial performance
13.7.5 Strategic initiatives
13.7.6 SWOT Analysis
13.8 ICON Plc.
13.8.1 Company overview
13.8.2 Service benchmarking
13.8.3 Organization structure & Team Composition
13.8.3.1 Team composition
13.8.4 Financial performance
13.8.5 Strategic initiatives
13.8.6 SWOT Analysis
13.9 Capgemini
13.9.1 Company overview
13.9.2 Service benchmarking
13.9.3 Organization structure & Team Composition
13.9.3.1 Team composition
13.9.4 Financial performance
13.9.5 Strategic initiatives
13.9.6 SWOT Analysis
13.10 ITClinical
13.10.1 Company overview
13.10.2 Service benchmarking
13.10.3 Organization structure & Team Composition
13.10.3.1 Team composition
13.10.4 Financial performance
13.10.5 SWOT Analysis
13.11 TAKE Solutions
13.11.1 Company overview
13.11.2 Service benchmarking
13.11.3 Organization structure & Team Composition
13.11.3.1 Team composition
13.11.4 Financial performance
13.11.5 Strategic initiatives
13.11.6 SWOT Analysis
13.12 PAREXEL International Corporation
13.12.1 Company overview
13.12.2 Service benchmarking
13.12.3 Organization structure & Team Composition
13.12.3.1 Team composition
13.12.4 Financial performance
13.12.5 Strategic initiatives
13.12.6 SWOT Analysis
13.13 BioClinica, Inc.
13.13.1 Company overview
13.13.2 Service benchmarking
13.13.3 Organization structure & Team Composition
13.13.3.1 Team composition
13.13.4 Financial performance
13.13.5 Strategic initiatives
13.13.6 SWOT Analysis
13.14 Wipro Limited
13.14.1 Company overview
13.14.2 Service benchmarking
13.14.3 Organization structure & Team Composition
13.14.3.1 Team composition
13.14.4 Financial performance
13.14.5 R&D expenditure
13.14.6 Strategic initiatives
13.14.7 SWOT Analysis
13.15 UNITED BIOSOURCE CORPORATION
13.15.1 Company overview
13.15.2 Service benchmarking
13.15.3 Organization structure & Team Composition
13.15.3.1 Team composition
13.15.4 Financial performance
13.15.5 Strategic initiatives
13.15.6 SWOT Analysis
13.16 FMD K&L
13.16.1 Company overview
13.16.2 Service benchmarking
13.16.3 Organization structure & Team Composition
13.16.3.1 Team composition
13.16.4 Financial performance
13.16.5 Strategic initiatives
13.16.6 SWOT Analysis
Chapter 14 Winning Strategies
14.1 Key Winning/Scoring Criteria
14.1.1 By categories
14.1.1.1 Pharmaceuticals
14.1.1.2 Biotech companies
14.1.1.3 Medical device companies
14.2 Key Vendor Selection Factors
14.2.1 By Category
14.2.2 BY Company size
14.2.2.1 Key Takeaways
Chapter 15 Switching Cost Analysis

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of abbreviation
TABLE 3 Types of ADRs
TABLE 4 Adverse Drug Events (ADEs) in hospitals
TABLE 5 List of regulations, by country
TABLE 6 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
TABLE 7 List of Major Deals & Acquisitions
TABLE 8 List of pharmacovigilance service providers
TABLE 9 North America pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 10 North America pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 11 North America pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 12 North America pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 13 North America pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 14 North America pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 15 U.S. pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 16 U.S. pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 17 U.S. pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 18 U.S. pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 19 U.S. pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 20 U.S. pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 21 Canada pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 22 Canada pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 23 Canada pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 24 Canada pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 25 Canada pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 26 Canada pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 27 Europe pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 28 Europe pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 29 Europe pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 30 Europe pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 31 Europe pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 32 Europe pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 33 U.K. pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 34 U.K. pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 35 U.K. pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 36 U.K. pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 37 U.K. pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 38 U.K. pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 39 Germany pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 40 Germany pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 41 Germany pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 42 Germany pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 43 Germany pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 44 Germany pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 45 France pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 46 France pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 47 France pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 48 France pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 49 France pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 50 France pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 51 Italy pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 52 Italy pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 53 Italy pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 54 Italy pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 55 Italy pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 56 Italy pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 57 Spain pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 58 Spain pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 59 Spain pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 60 Spain pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 61 Spain pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 62 Spain pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 63 Russia pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 64 Russia pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 65 Russia pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 66 Russia pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 67 Russia pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 68 Russia pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 69 Asia Pacific pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 70 Asia Pacific pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 71 Asia Pacific pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 72 Asia Pacific pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 73 Asia Pacific pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 74 Asia Pacific pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 75 Japan pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 76 Japan pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 77 Japan pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 78 Japan pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 79 Japan pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 80 Japan pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 81 China pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 82 China pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 83 China pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 84 China pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 85 China pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 86 China pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 87 India pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 88 India pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 89 India pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 90 India pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 91 India pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 92 India pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 93 Latin America pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 94 Latin America pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 95 Latin America pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 96 Latin America pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 97 Latin America pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 98 Latin America pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 99 Brazil pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 100 Brazil pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 101 Brazil pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 102 Brazil pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 103 Brazil pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 104 Brazil pharmacovigilance market, by end-use, 2016 - 2027 (USD Million
TABLE 105 Mexico pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 106 Mexico pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 107 Mexico pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 108 Mexico pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 109 Mexico pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 110 Mexico pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 111 MEA pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 112 MEA pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 113 MEA pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 114 MEA pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 115 MEA pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 116 MEA pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 117 South Africa pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 118 South Africa pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 119 South Africa pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 120 South Africa pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 121 South Africa pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 122 South Africa pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)
TABLE 123 KSA pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
TABLE 124 KSA pharmacovigilance market, by product life cycle, 2016 - 2027 (USD Million)
TABLE 125 KSA pharmacovigilance market, by type, 2016 - 2027 (USD Million)
TABLE 126 KSA pharmacovigilance market, by therapeutic area, 2016 - 2027 (USD Million)
TABLE 127 KSA pharmacovigilance market, by process flow, 2016 - 2027 (USD Million)
TABLE 128 KSA pharmacovigilance market, by end-use, 2016 - 2027 (USD Million)


List of Figures

FIG. 1 Market research process
FIG. 2 Data triangulation techniques
FIG. 3 Primary research pattern
FIG. 4 Primary interviews in North America
FIG. 5 Primary interviews in Europe
FIG. 6 Primary interviews in APAC
FIG. 7 Primary interviews in Latin America
FIG. 8 Primary interviews in MEA
FIG. 9 Market research approaches
FIG. 10 Value-chain-based sizing & forecasting
FIG. 11 QFD modeling for market share assessment
FIG. 12 Market formulation & validation
FIG. 13 Timeline of pharmacovigilance for a drug from development (premarket to post-marketing)
FIG. 14 Pharmacovigilance market snapshot
FIG. 15 Penetration & growth prospect mapping
FIG. 16 Pharmacovigilance market dynamics
FIG. 17 Pharmacovigilance market driver impact
FIG. 18 Pharmacovigilance market restraint impact
FIG. 19 Porter’s five force model
FIG. 20 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 21 Value Chain - Pharmacovigilance Process
FIG. 22 General safety and risk management process
FIG. 23 Pharmacovigilance Services
FIG. 24 Value Chain Analysis Based on Product Life Cycle Stages
FIG. 25 Pharmacovigilance & Patient Safety Services - Product Life Cycle
FIG. 26 PV department
FIG. 27 PV organization structure
FIG. 28 Estimated budget allocation of drug safety activities at global and country-level, 2019
FIG. 29 Comparison between estimated global and country-level drug safety budget allocation, 2019
FIG. 30 Average % of drug safety budget contributed by function at a global level
FIG. 31 Clinical trial cost by phase (%)
FIG. 32 The average monthly cost of illness due to ADRs
FIG. 33 Trending topics on social media (2017)
FIG. 34 ADR detection and from social media data
FIG. 35 Common literature automation tool flow
FIG. 36 Automation processes in PV
FIG. 37 Deterrents to Leveraging the Cloud (Oracle Survey)
FIG. 38 The three-step process to compute signal statistics from search log using big data
FIG. 39 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
FIG. 40 Pharmacovigilance market: Service provider movement analysis
FIG. 41 Pharmacovigilance Service provider dashboard
FIG. 42 Global In-house market, 2016 - 2027 (USD Million)
FIG. 43 Global contract outsourcing market, 2016 - 2027 (USD Million)
FIG. 44 Pharmacovigilance market: Type movement analysis
FIG. 45 Pharmacovigilance type dashboard
FIG. 46 Global spontaneous reporting market, 2016 - 2027 (USD Million)
FIG. 47 Global intensified ADR reporting market, 2016 - 2027 (USD Million)
FIG. 48 Global targeted spontaneous reporting market, 2016 - 2027 (USD Million)
FIG. 49 Global CEM market, 2016 - 2027 (USD Million)
FIG. 50 Global EHR mining market, 2016 - 2027 (USD Million)
FIG. 51 Pharmacovigilance market: Product life cycle movement analysis
FIG. 52 Pharmacovigilance market product dashboard
FIG. 53 Global Preclinical market, 2016 - 2027 (USD Million)
FIG. 54 Global Phase I market, 2016 - 2027 (USD Million)
FIG. 55 Global Phase II market, 2016 - 2027 (USD Million)
FIG. 56 Global Phase III market, 2016 - 2027 (USD Million)
FIG. 57 Global Phase IV market, 2016 - 2027 (USD Million)
FIG. 58 Pharmacovigilance market: Process flow movement analysis
FIG. 59 Pharmacovigilance market process flow dashboard
FIG. 60 Global case data management market, 2016 - 2027 (USD Million)
FIG. 61 Global case logging market, 2016 - 2027 (USD Million)
FIG. 62 Global case data analysis market, 2016 - 2027 (USD Million)
FIG. 63 Global medical reviewing and reporting market, 2016 - 2027 (USD Million)
FIG. 64 Global signal detection market, 2016 - 2027 (USD Million)
FIG. 65 Global adverse event logging market, 2016 - 2027 (USD Million)
FIG. 66 Global adverse event analysis market, 2016 - 2027 (USD Million)
FIG. 67 Global adverse event review & reporting market, 2016 - 2027 (USD Million)
FIG. 68 Global risk management system market, 2016 - 2027 (USD Million)
FIG. 69 Global Risk Evaluation System market, 2016 - 2027 (USD Million)
FIG. 70 Global risk mitigation system market, 2016 - 2027 (USD Million)
FIG. 71 Pharmacovigilance market: Therapeutic area movement analysis
FIG. 72 Pharmacovigilance market therapeutic area dashboard
FIG. 73 Global oncology market, 2016 - 2027 (USD Million)
FIG. 74 Global neurology market, 2016 - 2027 (USD Million)
FIG. 75 Global cardiology market, 2016 - 2027 (USD Million)
FIG. 76 Global respiratory systems market, 2016 - 2027 (USD Million)
FIG. 77 Global others market, 2016 - 2027 (USD Million)
FIG. 78 Pharmacovigilance market: End-use movement analysis
FIG. 79 Pharmacovigilance market end-use dashboard
FIG. 80 Global pharmaceuticals market, 2016 - 2027 (USD Million)
FIG. 81 Global biotechnology companies’ market, 2016 - 2027 (USD Million)
FIG. 82 Global medical device manufacturers market, 2016 - 2027 (USD Million)
FIG. 83 Global others market, 2016 - 2027 (USD Million)
FIG. 84 Regional market place: Key takeaways
FIG. 85 North America pharmacovigilance market share by countries, 2019
FIG. 86 Europe pharmacovigilance market share by countries, 2019
FIG. 87 Asia Pacific pharmacovigilance market share by countries, 2019
FIG. 88 Latin America pharmacovigilance market share by countries, 2019
FIG. 89 MEA pharmacovigilance market share by countries, 2019
FIG. 90 Regional outlook, 2019 & 2027
FIG. 91 North America pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 92 U.S. pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 93 Canada pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 94 Europe pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 95 U.K. pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 96 Germany pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 97 France pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 98 Italy pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 99 Spain pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 100 Russia pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 101 Asia Pacific Pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 102 Japan pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 103 China pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 104 India pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 105 Latin America pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 106 Brazil pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 107 Mexico pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 108 MEA pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 109 South Africa pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 110 Kingdom of Saudi Arabia pharmacovigilance market, 2016 - 2027 (USD Million)
FIG. 111 Market participant categorization
FIG. 112 Company market position analysis
FIG. 113 Estimated company market share analysis, 2019 (%)
FIG. 114 Organization Structure - Accenture
FIG. 115 SWOT - Accenture
FIG. 116 Organization Structure - Linical Americas.
FIG. 117 SWOT - Linical Americas
FIG. 118 Organization Structure - IQVIA
FIG. 119 SWOT - IQVIA
FIG. 120 Organization Structure - Cognizant
FIG. 121 SWOT - Cognizant
FIG. 122 Organization Structure - Laboratory Corporation of America Holdings
FIG. 123 SWOT - LABORATORY CORPORATION OF AMERICA HOLDINGS
FIG. 124 Organization Structure - IBM
FIG. 125 SWOT - IBM
FIG. 126 Organization Structure - ArisGlobal
FIG. 127 SWOT - ArisGlobal
FIG. 128 Organization Structure - ICON Plc
FIG. 129 SWOT - ICON Plc
FIG. 130 Organization Structure - Capgemini
FIG. 131 SWOT - Capgemini
FIG. 132 Organization Structure - ITC Clinical
FIG. 133 SWOT - ITC Clinical
FIG. 134 Organization Structure - Take Solutions
FIG. 135 SWOT - Take Solutions
FIG. 136 Organization Structure - Paraxel Corporation
FIG. 137 SWOT - PARAXEL
FIG. 138 Organization Structure - BioClinica, Inc.
FIG. 139 SWOT - BioClinica, Inc.
FIG. 140 Organization Structure - Wipro Ltd.
FIG. 141 SWOT - Wipro Ltd.
FIG. 142 Organization Structure - UBC
FIG. 143 SWOT - UBC
FIG. 144 Organization Structure FMD K&L
FIG. 145 SWOT - FMD K&L
FIG. 146 Commonly outsourced PV activities
FIG. 147 Vendor selection criteria

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ファーマコビジランスの世界市場2020-2027:製品ライフサイクル別、サービスプロバイダー別、種類別、治療領域別、プロセスフロー別、最終用途別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆